focusing on the use of LHRH agonists in hormone-receptor-positive (estrogen-receptor-positive and/or progesterone-receptor-positive) tumors. The analysis incorporated 16 trials and included 11,906 ...

Medically reviewed by Doru Paul, MD There is debate over the connection between vitamin D and estrogen-positive (ER-positive) ...

As aromatase inhibitors (AIs) are studied past the standard 5-year treatment duration in postmenopausal, estrogen/progesterone receptor-positive breast cancer patients, the possible side effect of ...

Cite this: SABCS 2024: New Treatment Options in HR+/HER2- Breast Cancer - Medscape - Jan 10, 2025.